CD22 and acute lymphoblastic leukemia: The clinical activity and safety of single-agent InO compared with standard intensive chemotherapy in adults with relapsed or refractory (R/R) CD22+ B-cell acute lymphoblastic leukemia (ALL) was assessed in the phase 3 INO-VATE trial [11].